Nephros Q2 revenue $2.3M (+44% YoY); net loss improves 35%; acquires GenArraytion, HDF module filed to FDA

NEPHROS INC

Net revenue $2.3M (+44% YoY); net loss improved 35% to $1.1M; adjusted EBITDA improved 46% to ($0.8M).
Water filtration segment rev $2.2M (+40% YoY); gross margin 56%; management expects 55-60%.
Acquired GenArraytion, Inc. in July 2021 to expand PCR testing and pathogen detection capabilities.
Filed FDA 510(k) for second-generation HDF Assist Module; anticipates clearance later this year for limited commercial launch.
Cash and equivalents of $8.3M as of June 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.